Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

NCT ID: NCT07157514

Last Updated: 2025-09-10

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 306 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-31
• Study Completion Date: 2034-02-28

Brief Summary

This is a multicenter, open-label study in people aged 18 and older with relapsed or refractory acute myeloid leukemia. It has two parts. In Phase 2, we are testing three radiation dose levels of 131I-apamistamab combined with fludarabine and low-dose whole-body radiation before stem cell transplant to find the safest and most effective dose. In Phase 3, patients will be randomly assigned to receive either this treatment combination or a standard of care regimen before transplant. The main goal is to see if the new approach helps people live longer. Phase 2 will enroll about 60 people, and Phase 3 will enroll about 246 people.

Detailed Description

This trial consists of a Phase 2 randomized dose optimization component and a Phase 3 randomized, controlled two-arm component. This is a multicenter, open-label, study of 131I-apamistamab, fludarabine and TBI, which will be compared to standard of care regimen prior to HSCT in the Phase 3 portion, in subjects, aged 18 years old or greater, with active, relapsed or refractory AML. Active, relapsed or refractory AML is defined as any one of the following: (1) primary induction failure (PIF) after 2 or more cycles of therapy, or (2) first early relapse after a remission duration of fewer than 6 months, or (3) relapse refractory to salvage combination therapy, or (4) second or subsequent relapse.

All subjects will undergo screening prior to randomization in the study. Screening will include collection of informed consent, physical examination, review of inclusion/exclusion criteria with associated testing, summarizing documented history of AML and any other malignant disease, and identification and medical clearance of an appropriate allogeneic hematopoietic stem cell (HSC) donor.

Subjects must have active R/R AML with 5-20% blasts in marrow, documented CD45 expression, ≥18 years of age, not suitable for a myeloablative conditioning regimen, Karnofsky ≥70, and a medically cleared 8/8 matched HSC donor. Key exclusions include >20% marrow blasts, prior HSCT, prior maximal organ radiation, active CNS leukemia, significant cardiac disease, abnormal QTcF >450 ms, uncontrolled infection, or active malignancy within 2 years

Conditions

Acute Leukemia; Myeloid Leukemia; Acute Myelogenous Leukemia; Acute Myeloid Leukemia; Acute Myeloid Leukemia, in Relapse; Myelogenous Leukemia; Myelogenous Leukemia, Acute; Myelogenous Leukemia in Relapse; Transplant-Related Disorder; Allogeneic Disease; Refractory AML

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A: Experimental: I131-apamistamab + Fludarabine + TBI

Participants receive a dosimetric dose and then a treatment dose of I131-apamistamab (at the marrow dose selected in Phase 2), followed by fludarabine 30 mg/m² IV daily on Days -6 through -2 and total body irradiation (TBI) 200 cGy on Day -1 prior to allogeneic hematopoietic stem cell transplant (HSCT) on Day 0.

Graft-versus-host disease (GvHD) prophylaxis per investigator's choice:

• Post-transplant cyclophosphamide (50 mg/kg on Days +3 and +4) + tacrolimus + mycophenolate mofetil, OR
• Low-dose methotrexate + tacrolimus.

Group Type: EXPERIMENTAL

131I-apamistamab

Intervention Type: DRUG

Iodine-131 radiolabeled anti-CD45 monoclonal antibody (apamistamab). Administered IV as a dosimetric dose followed by treatment dose.

Fludarabine

Intervention Type: DRUG

Fludarabine phosphate, 30 mg/m² IV daily on Days -6 through -2.

Cyclophosphamide

Intervention Type: DRUG

Cyclophosphamide

Total Body Irradiation (TBI)

Intervention Type: RADIATION

TBI, 200 cGy on Day -1 prior to HSCT.

Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Intervention Type: BIOLOGICAL

Unmodified, G-CSF-mobilized donor stem cells infused on Day 0.

Arm B: Active Comparator - Standard of Care Conditioning Regimen

Participants receive standard of care conditioning regimen prior to allogeneic hematopoietic stem cell transplant (HSCT) on Day 0

GvHD prophylaxis per investigator's choice:

• Post-transplant cyclophosphamide (50 mg/kg on Days +3 and +4) + tacrolimus + mycophenolate mofetil, OR
• Low-dose methotrexate + tacrolimus.

Group Type: ACTIVE_COMPARATOR

Fludarabine

Intervention Type: DRUG

Fludarabine phosphate, 30 mg/m² IV daily on Days -6 through -2.

Cyclophosphamide

Intervention Type: DRUG

Cyclophosphamide

Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Intervention Type: BIOLOGICAL

Unmodified, G-CSF-mobilized donor stem cells infused on Day 0.

Interventions

131I-apamistamab

Iodine-131 radiolabeled anti-CD45 monoclonal antibody (apamistamab). Administered IV as a dosimetric dose followed by treatment dose.

Intervention Type: DRUG

Fludarabine

Fludarabine phosphate, 30 mg/m² IV daily on Days -6 through -2.

Intervention Type: DRUG

Cyclophosphamide

Cyclophosphamide

Intervention Type: DRUG

Total Body Irradiation (TBI)

TBI, 200 cGy on Day -1 prior to HSCT.

Intervention Type: RADIATION

Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Unmodified, G-CSF-mobilized donor stem cells infused on Day 0.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Have active, relapsed, or refractory AML with ≥5% and ≤20% blasts in the marrow.

2. 2R/R AML is defined as one of the following: Primary induction failure after ≥2 cycles of therapy, first early relapse after remission <6 months, relapse refractory to salvage combination therapy or second or subsequent relapse

3. Documented CD45 expression by leukemic cells via flow cytometry.

4. ≥18 years of age and not suitable for myeloablative conditioning regimen.

5. Circulating blast count <10,000/mm³ (hydroxyurea allowed).

6. Calculated creatinine clearance (Cockcroft-Gault) >50 mL/min.

7. Adequate hepatic function: AST/ALT ≤2 × ULN; total bilirubin ≤1.5 × ULN (≤3 × ULN if due to underlying malignancy or Gilbert's).

8. Karnofsky performance score ≥70.

9. Expected survival >60 days.

10. Central venous catheter line in place before study treatment.

11. 8/8 HLA-matched related or unrelated donor (HLA-A, HLA-B, HLA-C, DRB1).

12. Women of childbearing potential must be surgically sterile or use acceptable contraception through 1-year post-transplant.

13. Men with partners of childbearing potential must be surgically sterile or use acceptable contraception through 12 weeks after last dose.

14. Able to understand procedures, provide informed consent, and comply with study requirements.

Exclusion Criteria

1. Positive human anti-mouse antibody (HAMA) at screening.

2. >20% leukemic blasts in marrow.

3. Prior radiation to maximally tolerated levels of any critical organ.

4. Active CNS leukemia (blasts in CSF or CNS chloromas).

5. Prior allogeneic or autologous HSCT.

6. Candidates suitable for myeloablative conditioning.

7. Clinically significant cardiac disease, including: NYHA Class III or IV heart failure, Clinically significant arrhythmias (ventricular tachycardia, ventricular fibrillation, Torsade de Pointes), Myocardial infarction with uncontrolled angina within 6 months, Clinically significant congestive heart failure or cardiomyopathy

8. QTcF >450 ms after correction of electrolytes (unless paced rhythm or investigator deems eligible; cardiology consult optional).

9. Positive HIV, HBV, or HCV test (exceptions: vaccinated HBV, or positive hepatitis markers with adequate organ function).

10. Active, uncontrolled infection.

11. Acute promyelocytic leukemia (t[15;17]).

12. Active malignancy within 2 years, except: Myelodysplastic syndrome, Treated non-melanoma skin cancer, Completely resected stage 0-1 melanoma (>1 year from resection), Carcinoma in situ or cervical intraepithelial neoplasia, Organ-confined prostate cancer without progression

13. Inability to tolerate diagnostic or therapeutic procedures, particularly radiation isolation.

14. Received anti-leukemic therapy within 14 days prior to randomization (hydroxyurea allowed up to day of 131I-apamistamab).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Actinium Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Madhuri Vusirikala, MD

Role: CONTACT

mvusirikala@actiniumpharma.com

347-814-2268

Other Identifiers

AIM-300

Identifier Type: -

Identifier Source: org_study_id